BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 16234526)

  • 1. Phase I study of O6-benzylguanine and temozolomide administered daily for 5 days to pediatric patients with solid tumors.
    Warren KE; Aikin AA; Libucha M; Widemann BC; Fox E; Packer RJ; Balis FM
    J Clin Oncol; 2005 Oct; 23(30):7646-53. PubMed ID: 16234526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies.
    Britten CD; Rowinsky EK; Baker SD; Agarwala SS; Eckardt JR; Barrington R; Diab SG; Hammond LA; Johnson T; Villalona-Calero M; Fraass U; Statkevich P; Von Hoff DD; Eckhardt SG
    Clin Cancer Res; 1999 Jul; 5(7):1629-37. PubMed ID: 10430061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma.
    Quinn JA; Desjardins A; Weingart J; Brem H; Dolan ME; Delaney SM; Vredenburgh J; Rich J; Friedman AH; Reardon DA; Sampson JH; Pegg AE; Moschel RC; Birch R; McLendon RE; Provenzale JM; Gururangan S; Dancey JE; Maxwell J; Tourt-Uhlig S; Herndon JE; Bigner DD; Friedman HS
    J Clin Oncol; 2005 Oct; 23(28):7178-87. PubMed ID: 16192602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lomeguatrib, a potent inhibitor of O6-alkylguanine-DNA-alkyltransferase: phase I safety, pharmacodynamic, and pharmacokinetic trial and evaluation in combination with temozolomide in patients with advanced solid tumors.
    Ranson M; Middleton MR; Bridgewater J; Lee SM; Dawson M; Jowle D; Halbert G; Waller S; McGrath H; Gumbrell L; McElhinney RS; Donnelly D; McMurry TB; Margison GP
    Clin Cancer Res; 2006 Mar; 12(5):1577-84. PubMed ID: 16533784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I trial of single-dose temozolomide and continuous administration of o6-benzylguanine in children with brain tumors: a pediatric brain tumor consortium report.
    Broniscer A; Gururangan S; MacDonald TJ; Goldman S; Packer RJ; Stewart CF; Wallace D; Danks MK; Friedman HS; Poussaint TY; Kun LE; Boyett JM; Gajjar A
    Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6712-8. PubMed ID: 18006772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer.
    Dhodapkar M; Rubin J; Reid JM; Burch PA; Pitot HC; Buckner JC; Ames MM; Suman VJ
    Clin Cancer Res; 1997 Jul; 3(7):1093-100. PubMed ID: 9815788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I clinical and pharmacological study of O6-benzylguanine followed by carmustine in patients with advanced cancer.
    Schilsky RL; Dolan ME; Bertucci D; Ewesuedo RB; Vogelzang NJ; Mani S; Wilson LR; Ratain MJ
    Clin Cancer Res; 2000 Aug; 6(8):3025-31. PubMed ID: 10955780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extended phase I evaluation of vincristine, irinotecan, temozolomide, and antibiotic in children with refractory solid tumors.
    McNall-Knapp RY; Williams CN; Reeves EN; Heideman RL; Meyer WH
    Pediatr Blood Cancer; 2010 Jul; 54(7):909-15. PubMed ID: 20405511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II study of O6-benzylguanine and temozolomide in pediatric patients with recurrent or progressive high-grade gliomas and brainstem gliomas: a Pediatric Brain Tumor Consortium study.
    Warren KE; Gururangan S; Geyer JR; McLendon RE; Poussaint TY; Wallace D; Balis FM; Berg SL; Packer RJ; Goldman S; Minturn JE; Pollack IF; Boyett JM; Kun LE
    J Neurooncol; 2012 Feb; 106(3):643-9. PubMed ID: 21968943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma.
    Quinn JA; Jiang SX; Reardon DA; Desjardins A; Vredenburgh JJ; Gururangan S; Sampson JH; McLendon RE; Herndon JE; Friedman HS
    Cancer; 2009 Jul; 115(13):2964-70. PubMed ID: 19402172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma.
    Quinn JA; Jiang SX; Reardon DA; Desjardins A; Vredenburgh JJ; Rich JN; Gururangan S; Friedman AH; Bigner DD; Sampson JH; McLendon RE; Herndon JE; Walker A; Friedman HS
    Neuro Oncol; 2009 Oct; 11(5):556-61. PubMed ID: 19289491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of docetaxel and topotecan in patients with solid tumors.
    Tkaczuk KH; Zamboni WC; Tait NS; Meisenberg BR; Doyle LA; Edelman MJ; Hausner PF; Egorin MJ; Van Echo DA
    Cancer Chemother Pharmacol; 2000; 46(6):442-8. PubMed ID: 11138457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: a Children's Oncology Group Study.
    Bagatell R; Norris R; Ingle AM; Ahern C; Voss S; Fox E; Little AR; Weigel BJ; Adamson PC; Blaney S
    Pediatr Blood Cancer; 2014 May; 61(5):833-9. PubMed ID: 24249672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy.
    Raizer JJ; Malkin MG; Kleber M; Abrey LE
    Neuro Oncol; 2004 Jul; 6(3):247-52. PubMed ID: 15279717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies.
    Hammond LA; Eckardt JR; Baker SD; Eckhardt SG; Dugan M; Forral K; Reidenberg P; Statkevich P; Weiss GR; Rinaldi DA; Von Hoff DD; Rowinsky EK
    J Clin Oncol; 1999 Aug; 17(8):2604-13. PubMed ID: 10561328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I. Trial of irinotecan and temozolomide in patients with solid tumors.
    Jones SF; Gian VG; Greco FA; Miranda FT; Shipley DL; Thompson DS; Hainsworth JD; Toomey MA; Willcutt NT; Burris HA
    Oncology (Williston Park); 2003 May; 17(5 Suppl 5):41-5. PubMed ID: 12800606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I Trial of G3139, a bcl-2 antisense oligonucleotide, combined with doxorubicin and cyclophosphamide in children with relapsed solid tumors: a Children's Oncology Group Study.
    Rheingold SR; Hogarty MD; Blaney SM; Zwiebel JA; Sauk-Schubert C; Chandula R; Krailo MD; Adamson PC;
    J Clin Oncol; 2007 Apr; 25(12):1512-8. PubMed ID: 17442993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I trial of intravenous cisplatin-topotecan chemotherapy for three consecutive days in patients with advanced solid tumors: parallel topotecan escalation in two fixed platinum dosing schemes.
    Pentheroudakis G; Briasoulis E; Karavassilis V; Mauri D; Tzamakou E; Rammou D; Pavlidis N
    Chemotherapy; 2005 May; 51(2-3):154-61. PubMed ID: 15886476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thresholds of O6-alkylguanine-DNA alkyltransferase which confer significant resistance of human glial tumor xenografts to treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea or temozolomide.
    Kokkinakis DM; Bocangel DB; Schold SC; Moschel RC; Pegg AE
    Clin Cancer Res; 2001 Feb; 7(2):421-8. PubMed ID: 11234899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 1b study of lenvatinib (E7080) in combination with temozolomide for treatment of advanced melanoma.
    Hong DS; Kurzrock R; Falchook GS; Andresen C; Kwak J; Ren M; Xu L; George GC; Kim KB; Nguyen LM; O'Brien JP; Nemunaitis J
    Oncotarget; 2015 Dec; 6(40):43127-34. PubMed ID: 26503473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.